Aberdeen Group’s PRA Health Sciences, Inc. PRAH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q3 | – | Sell |
-14,200
| Closed | -$2.35M | – | 1077 |
|
|
2021
Q2 | $2.35M | Sell |
14,200
-12,250
| -46% | -$2.05M | 0.01% | 738 |
|
|
2021
Q1 | $4.06M | Sell |
26,450
-196,720
| -88% | -$26.7M | 0.01% | 682 |
|
|
2020
Q4 | $28M | Sell |
223,170
-137,980
| -38% | -$15.4M | 0.07% | 254 |
|
|
2020
Q3 | $36.6M | Sell |
361,150
-141,286
| -28% | -$14.4M | 0.1% | 169 |
|
|
2020
Q2 | $48.9M | Sell |
502,436
-211,174
| -30% | -$19.7M | 0.13% | 142 |
|
|
2020
Q1 | $59.3M | Sell |
713,610
-62,300
| -8% | -$6.08M | 0.19% | 109 |
|
|
2019
Q4 | $86.3M | Sell |
775,910
-478,400
| -38% | -$49.2M | 0.21% | 99 |
|
|
2019
Q3 | $124M | Sell |
1,254,310
-152,388
| -11% | -$15.1M | 0.31% | 83 |
|
|
2019
Q2 | $140M | Buy |
1,406,698
+632,880
| +82% | +$60.4M | 0.31% | 77 |
|
|
2019
Q1 | $85.3M | Sell |
773,818
-33,774
| -4% | -$3.53M | 0.18% | 108 |
|
|
2018
Q4 | $72.4M | Buy |
807,592
+674,758
| +508% | +$68.3M | 0.17% | 116 |
|
|
2018
Q3 | $14.6M | Buy |
132,834
+3,131
| +2% | +$326K | 0.03% | 435 |
|
|
2018
Q2 | $12.1M | Buy |
129,703
+6,698
| +5% | +$577K | 0.02% | 453 |
|
|
2018
Q1 | $10.2M | Buy |
+123,005
| New | +$10.9M | 0.02% | 447 |
|
Other funds holding PRAH
Aberdeen Group's PRAH Position: Q3 2021 in Review
Aberdeen Group sold out of PRA Health Sciences, Inc. (PRAH) in Q3 2021, closing a stake of 14,200 shares — an estimated $2.35M sold.
Aberdeen Group first reported a position in PRAH in Q1 2018 and held it in 14 quarters. The position peaked at $140M in Q2 2019. 1 fund tracked by Wall St. Rank holds PRAH as of Q3 2021.
- Aberdeen Group reported no remaining PRA Health Sciences, Inc. position as of Q3 2021 after selling out during the quarter.
- Aberdeen Group sold 14,200 PRA Health Sciences, Inc. shares in Q3 2021, an estimated $2.35M.
- Aberdeen Group first reported a position in PRA Health Sciences, Inc. in Q1 2018 and held it in 14 quarters.
- Aberdeen Group's PRA Health Sciences, Inc. position peaked at $140M in Q2 2019.
- 1 fund tracked by Wall St. Rank held PRA Health Sciences, Inc. as of Q3 2021.
Based on Aberdeen Group's 13F filing for Q3 2021, filed 15 Nov 2021.